Articles from MMS Holdings

MMS Holdings, a global, data-focused clinical research organization (CRO), today named UK-based Ben Dudley as President, extending his existing role as Chief Commercial Officer. The expanded position further supports MMS’ vision and growth as a science-led CRO, helping sponsors worldwide navigate complexity, reduce risk, and advance clinical programs through its integrated biometrics and regulatory capabilities. Dudley’s appointment reinforces MMS’ increasing international presence and builds on strong recent momentum in Europe, including the 2025 acquisition of Exploristics, a Belfast-based biostatistics and data science company.

MMS, a global, data-focused clinical research organization (CRO), announced today that it has been chosen by Friends of Cancer Research (Friends), a leading nonprofit dedicated to accelerating innovation in cancer research, to support the development of practical decision frameworks to inform the interpretation of interim overall survival (OS) data in oncology clinical trials.

MMS, an award-winning, data-focused clinical research organization (CRO), announced today its acquisition of Exploristics, a leading biostatistics and data science company based in Belfast, Northern Ireland. The acquisition will add the company’s flagship product, KerusCloud®, a state-of-the-art, cloud-based statistical modeling and simulation platform to MMS’ data-driven approach towards efficient drug development.

MMS, a data-focused clinical research organization (CRO), announced today that Ben Dudley has been appointed as the company’s new Chief Commercial Officer (CCO). Based in the UK, Ben Dudley brings more than 25 years of life sciences expertise on the CRO and Sponsor side, holding previous operational and commercial leadership roles at Parexel, Covance, and AstraZeneca.

MMS, a leading, data-focused clinical research organization (CRO), announced today that the company has expanded its biometrics leadership within European operations by hiring James Zee as Director of Global Statistical Programming. Based in the United Kingdom (UK), Zee brings 25 years of experience across several leading pharmaceutical companies, including AstraZeneca, MSD, Novartis, Roche, and others.

MMS, a data-focused Clinical Research Organization (CRO), announced MAPS Public Benefit Corporation (MAPS PBC) submitted a New Drug Application (NDA) to the FDA for MDMA (midomafetamine capsules) used in combination with psychological intervention, which includes psychotherapy, or talk therapy, and other supportive services provided by a qualified healthcare provider. MAPS PBC is developing investigational MDMA-assisted therapy for individuals with post-traumatic stress disorder (PTSD). Over a year ago, MAPS PBC selected MMS as its CRO partner for the development of NDA for MDMA-assisted therapy for PTSD. If approved, MDMA-assisted therapy could be the first psychedelic-assisted therapy.

MMS Holdings, an award-winning, data-focused CRO, announced today the addition of Dr. Philip Breitfeld and Dr. Bernhardt Zeiher to its board of scientific advisors. Both industry leaders in innovative clinical trial delivery solutions, Dr. Breitfeld and Dr. Zeiher’s additions as advisors expand MMS’ therapeutic area expertise to support growth in different therapeutic areas.

MMS Holdings, a data-focused contract research organization (CRO) – announced its partnership with the Institute for Advanced Clinical Trials (I-ACT) to accelerate the development of life-saving therapeutics, including vaccines, medicines, and medical devices for children.

MMS Holdings (MMS) – an award-winning, data-focused contract research organization (CRO) – announces the expansion of its leadership team with the appointment of Chris Schoonmaker as Chief Operating Officer and Ashu Tandon as Chief Commercial Officer. This comes as the company was recognized in the 2023 Top Workplace USA awards, a national list of organizations with strong company cultures and high employee satisfaction rates, and a Great Place to Work in India.

MMS Holdings, a data-focused contract research organization (CRO), has been named a 2022 award winner of the Michigan Top Workplaces by the Detroit Free Press Top Workplaces. This is the second year that MMS has been recognized with this honor.

MMS Holdings, a data-focused Contract Research Organization (CRO), is pleased to announce a strategic partnership with Medidata, a Dassault Systèmes company, to provide clients a full range of solutions for clinical data management (CDM) and decentralized clinical trial (DCT) technologies, including Medidata’s unified platform and Rave EDC (Electronic Data Capture).

MMS Holdings, a data-focused clinical research organization, was recognized in the 2022 Top Workplace USA awards, a national list of organizations with strong company cultures and high employee satisfaction rates.

MMS Holdings – a data-focused CRO – announced this week the addition of Kevin Chartier, Ph.D., as Principal Advisor of Biostatistics and Submissions Planning. Chartier will work with the biostatistics team across MMS global operations to support Sponsors with complex studies and submissions.

MMS Holdings (MMS) – a data-focused CRO – provided regulatory strategy support to Praxis Bioresearch in the development of a therapeutic for apathy in Alzheimer’s disease. This comes as Praxis was awarded a $2.9 Million Fast-Track SBIR Grant to advance the company’s lead development candidate, PRX-P4-003.

MMS Holdings Inc. (MMS) - an award-winning, data-focused CRO – announced the release of SmartStart™ Tech-Enabled Templates to reduce time and effort in the document content creation process while increasing the quality of deliverables.